Project Grant R21AI187983
- This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
- This Project Grant award of $1,553,810 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate a genomic surveillance approach for monitoring artemisinin resistance in Plasmodium falciparum malaria in Africa. The project aims to identify genetic mutations and altered biological functions associated with artemisinin resistance, which is a critical concern as resistance emerges...
- This $1,174,636 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) supports the development of next-generation ELQ compounds for the treatment and prevention of malaria. The research aims to identify novel, rapidly acting anti-malarial drugs to target the blood and liver stages of the Plasmodium falciparum parasite, as well as formulations suitable for long-acting...
- This federal Project Grant award of $791,864 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify molecular factors controlling chromatin organization and gene regulation in the malaria parasite Plasmodium falciparum. The research aims to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and sexual differentiation, with the goal...
- This $258,644 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to develop novel 4-aminoquinoline therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The grant recipient, Oregon Health & Science University, will use an iterative medicinal chemistry approach to select compounds with potent antiplasmodial activity, favorable pharmacokinetic...
- This $122,597 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to analyze the function and antibody-mediated inhibition of the malaria vaccine candidate protein PF3D7_1136200. The project aims to characterize this promising but previously uncharacterized blood-stage malaria antigen, with the goal of advancing development of a highly efficacious malaria vaccine. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $807,330 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research focused on improving antibody-based protection against Plasmodium falciparum (P. falciparum) and Plasmodium vivax (P. vivax) malaria. The project aims to identify new antibody variants with at least...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,808 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis, Missouri. The funding will support research to identify heme-binding proteins in the malaria parasite Plasmodium falciparum and investigate their role in maintaining heme homeostasis. The project aims to better understand how the parasite detoxifies heme, an essential but redox-active...
- This Project Grant award of $699,814 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to study molecular mechanisms of Plasmodium parasite invasion in Anopheles mosquito midguts to identify novel targets for transmission-blocking malaria vaccines. The key products and services to be delivered under this award include: Functional characterization of identified mosquito and parasite proteins that mediate...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), will provide $187,056 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the role of erythrocyte glycolysis in the Plasmodium falciparum lifecycle as a potential antimalarial strategy. The research aims to determine how disrupting erythrocyte glycolysis affects the growth and progression of...
This federal Project Grant award of $426,938, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore the combined use of human anti-RH5 monoclonal antibodies and small molecule inhibitors against asexual Plasmodium falciparum malaria parasites. The research aims to assess the potential for additive, synergistic, or antagonistic effects of these combined interventions in inhibiting merozoite invasion of red blood cells, which is a critical step in the malaria life cycle. This 2-year project, awarded to The Johns Hopkins University, seeks to guide further development of novel antimalarial therapeutic approaches by leveraging advanced genetic and inhibitor studies to understand the multistep merozoite invasion process.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $426.9k | 7/29/25 |